KVL-9
KVL‑9 is an intermediate for constructing KRAS-degrading antibody-drug conjugates (DAC), consisting of a KRAS small-molecule binder, a spacer, a VHL-recruiting ligand, and a cleavable antibody linker. By conjugating with tumor antigen-targeting antibodies, KVL‑9 enables antigen-dependent intracellular delivery and induces VHL‑mediated ubiquitin‑proteasome degradation of KRAS protein. KVL‑9 can be used for the synthesis of DACs. KVL‑9 is applicable to cancer research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 3113309-33-1
- 화학식: C140H192F2N38O34S2
- 분자량:3053.38
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
KVL-9 achieves antigen-dependent intracellular delivery via conjugation with tumor antigen-targeting antibodies, releases KRAS degrader inside tumor cells, and degrades KRAS protein through the VHL-mediated ubiquitin-proteasome pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 3113309-33-1
-
분자량 3053.38
-
화학식 C140H192F2N38O34S2
-
SMILES
C[C@@]1(C2=NC(C3=NC(N4[C@H](CN(CCC4)CCCCOC5=CN(N=N5)[C@@H](C(C)C)C(N6[C@@H](C[C@H](C6)O)C(N[C@H](C7=C(C=C(C8=C(C)N=CS8)C(F)=C7)OCC9=CC=C(C=C9)NC([C@H](C)NC([C@H](C)NC(CCC%10=C(C(F)=C(N%11C(C=CC%11=O)=O)C=C%10)OCCCC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)C)=NC=C3)=NO2)C%12=C(CCC1)SC(N)=C%12C#N
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. HY-186226-1.pdf
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)